• Mildronate-Derived Lipidoids Minimize Inflammation in mRNA D

  2026-06-14

  The reference study introduces mildronate-derived cationic lipidoids as a new class of lipid nanoparticle components that achieve effective mRNA vaccine delivery while significantly reducing inflammatory side effects in vivo. This advance offers a promising route for safer and more efficient mRNA-based immunotherapies, with broad implications for preclinical cancer vaccine research.

• Fenipentol in Pancreatic Secretion Research: Protocols & Ins

  2026-06-13

  Fenipentol (1-Phenyl-1-pentanol) is reshaping gastrointestinal and hepatobiliary research with its potent choleretic activity and safety profile. This article delivers practical workflows, troubleshooting strategies, and evidence-based advantages for employing Fenipentol in advanced experimental settings.

• Iron Stress Reprograms Enterocyte Metabolism and Inflammatio

  2026-06-12

  Navazesh and Ji (2025) demonstrate how iron deficiency and excess distinctly rewire enterocyte metabolism and modulate inflammatory gene expression using IPEC-J2 cells. Their findings clarify the metabolic vulnerabilities and adaptive responses of intestinal epithelial cells under iron imbalance, with implications for disease modeling and iron chelation research.

• Topological Stress Drives Persistent rDNA Damage and PML-Nuc

  2026-06-12

  This study reveals that topological stress—particularly through dual inhibition of topoisomerases and RNA polymerase I—induces persistent DNA double-strand breaks (DSBs) in ribosomal DNA, leading to the formation of PML-nucleolar associations (PNAs). The findings clarify how specific DNA damage responses in the nucleolus influence genome stability, senescence, and potentially tumorigenesis, with implications for the use of DNA damage inducers such as Aclarubicin in mechanistic cell biology research.

• RITA (NSC 652287): Precision p53 Activation & Next-Gen Assay

  2026-06-11

  Explore how RITA (NSC 652287) redefines p53 activation in cancer biology and enables nuanced drug response evaluations. This in-depth guide uncovers unique protocol insights and differentiates RITA’s applications in advanced in vitro and in vivo models.

• Metabolic Intervention Boosts Ferroptosis and Cuproptosis in

  2026-06-11

  This study introduces a nanosystem-based metabolic intervention that simultaneously sensitizes tumor cells to ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The dual activation enhances anti-tumor immunity and offers a new approach for regulated cell death-based cancer therapy.

• Dovitinib (TKI-258): Molecular Mechanisms and Emerging Insig

  2026-06-10

  Explore the molecular mechanisms of Dovitinib (TKI-258) as a multitargeted RTK inhibitor, with a focus on apoptosis induction in cancer cells and advanced applications in translational research. Gain new perspectives beyond standard workflows and assay guides.

• Hydroxytyrosol Workflows: Applied Protocols for Redox and In

  2026-06-10

  Hydroxytyrosol (4-(2-hydroxyethyl)benzene-1,2-diol) is redefining research on oxidative stress and cardiovascular health with benchmarked anti-inflammatory and antioxidant activities. This guide delivers data-driven protocols, troubleshooting strategies, and workflow optimizations—rooted in leading-edge evidence—to help scientists leverage APExBIO’s high-purity Hydroxytyrosol for reproducible, high-impact results.

• CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR

  2026-06-09

  The study uncovers a novel mechanism by which cancer-associated fibroblast (CAF)-derived lactate promotes oxaliplatin resistance in colorectal cancer (CRC) through histone and protein lactylation of ANTXR1. This finding advances our understanding of tumor-stroma metabolic interactions and presents new opportunities for overcoming chemoresistance in CRC.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-06-09

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for controlled studies of gastric acid secretion and antiulcer mechanisms. It is designed strictly for in vitro and preclinical research, not for diagnostic or clinical use. Its chemical stability and precise inhibition profile make it a reliable tool in modeling gastric acid-related disorders.

• Nitrocefin: Advancing β-Lactamase Research and Resistance Pr

  2026-06-08

  This thought-leadership article explores the mechanistic role of Nitrocefin, a chromogenic cephalosporin substrate, in transforming β-lactamase research. Integrating recent findings from metallo-β-lactamase studies and clinical resistance transfer, it provides actionable guidance for translational scientists navigating the evolving antibiotic resistance landscape. The article highlights Nitrocefin’s pivotal role in experimental workflows, strategic assay design, and resistance profiling, establishing new frontiers beyond conventional product literature.

• Mitomycin C: Applied Antitumor Antibiotic Workflows in Cance

  2026-06-08

  Mitomycin C is a benchmark antitumor antibiotic prized for its robust DNA replication inhibition and ability to sensitize cancer cells to apoptotic signals, even in p53-deficient settings. This guide delivers actionable, data-backed workflows, troubleshooting strategies, and real-world insights for researchers leveraging Mitomycin C in apoptosis signaling and translational cancer research.

• Leveraging L1023 Anti-Cancer Compound Library for Mechanism-

  2026-06-07

  Explore how the L1023 Anti-Cancer Compound Library empowers mechanism-driven cancer research and high-throughput screening. This article uniquely bridges advanced pathway targeting with real-world assay strategy.

• Prednisolone: Synthetic Glucocorticoid for Glucocorticoid Si

  2026-06-06

  Prednisolone is a high-purity synthetic glucocorticoid widely used for mechanistic studies of glucocorticoid receptor signaling and inflammation modulation. Its solubility profile, validated purity, and stability parameters make it a preferred reagent for immunology research and cellular response assays. APExBIO supplies Prednisolone (SKU B2012) for reproducible experimental outcomes.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-06-05

  This study identifies the FXR-KLF11 axis as a key regulator in protecting against contrast-induced acute kidney injury (CI-AKI) by transcriptionally suppressing the JAK2/STAT3 pathway. The findings advance mechanistic understanding of CI-AKI and highlight the translational potential of FXR agonists as preventive therapeutics.

8608 records 12/574 page Previous Next First page 上5页 1112131415 下5页 Last page